Neoadjuvant therapy in resectable pancreatic cancer: A critical review

Cancer Treatment Reviews

Volumn 39, Issue 5, 2013, Pages 518-524

  Belli, Carmen ^a   Cereda, Stefano ^a   Anand, Santosh ^a   Reni, Michele ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Neoadjuvant therapy; Pancreatic cancer; Radiotherapy; Resectable disease; Surgery

Indexed keywords

CISPLATIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; PACLITAXEL; TEGAFUR;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; HUMAN; INTRAOPERATIVE RADIOTHERAPY; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PREOPERATIVE TREATMENT; RADIATION DOSE; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

EID: 84877006160     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.09.008     Document Type: Review

References (63)

1. Neoptolemos J.P., Stocken D.D., Dunn J.A., et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001, 234:758-768.
2. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
3. Ueno H., Kosuge T., Matsuyama Y., et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009, 101:908-915.
4. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
5. Schnelldorfer T., Ware A.L., Sarr M.G., et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann Surg 2008, 247:456-462.
6. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
7. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299:1019-1026.
8. Neoptolemos J., Stocken D.D., Bassi C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
9. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
10. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782. discussion 82-84.
11. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997, 15:928-937.
12. Palmer D.H., Stocken D.D., Hewitt H., et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007, 14:2088-2096.
13. Varadhachary G.R., Wolff R.A., Crane C.H., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3487-3495.
14. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496-3502.
15. Hoffman J.P., Lipsitz S., Pisansky T., Weese J.L., Solin L., Benson A.B. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998, 16:317-323.
16. White R.R., Hurwitz H.I., Morse M.A., et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001, 8:758-765.
17. Moutardier V., Magnin V., Turrini O., et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004, 60:437-443.
18. Ishikawa O., Ohigashi H., Imaoka S., et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?. Arch Surg 1994, 129:1075-1080.
19. Evans D.B., Rich T.A., Byrd D.R., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992, 127:1335-1339.
20. Pisters P.W., Abbruzzese J.L., Janjan N.A., et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998, 16:3843-3850.
21. Lawrence T.S., Chang E.Y., Hahn T.M., Hertel L.W., Shewach D.S. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys 1996, 34:867-872.
22. Pisters P.W., Wolff R.A., Janjan N.A., et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002, 20:2537-2544.
23. Calvo F.A., Matute R., Garcia-Sabrido J.L., et al. Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome. Am J Clin Oncol 2004, 27:343-349.
24. Hoffman J.P., Weese J.L., Solin L.J., et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995, 169:71-77. discussion 7-8.
25. Moutardier V., Giovannini M., Lelong B., et al. A phase II single institutional experience with preoperative radiochemotherapy in pancreatic adenocarcinoma. Eur J Surg Oncol 2002, 28:531-539.
26. Magnin V., Moutardier V., Giovannini M.H., et al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003, 55:1300-1304.
27. Turrini O., Viret F., Moureau-Zabotto L., et al. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. Oncology 2009, 76:413-419.
28. Mornex F., Girard N., Scoazec J.Y., et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 2006, 65:1471-1478.
29. Heinrich S., Pestalozzi B.C., Schafer M., et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:2526-2531.
30. Philip P.A., Zalupski M.M., Vaitkevicius V.K., et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001, 92:569-577.
31. Talamonti M.S., Small W., Mulcahy M.F., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006, 13:150-158.
32. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
33. Philip P.A., Benedetti J., Corless C.L., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010, 28:3605-3610.
34. Kindler H.L., Ioka T., Richel D.J., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011, 12:256-262.
35. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23:8033-8040.
36. Yeung R.S., Weese J.L., Hoffman J.P., et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II Study. Cancer 1993, 72:2124-2133.
37. Reni M., Balzano G., Aprile G., et al. Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol 2012, 19:2256-2263.
38. Picozzi V.J., Abrams R.A., Decker P.A., et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011, 22:348-354.
39. Marten A., Schmidt J., Debus J., et al. CapRI: final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-α2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). J Clin Oncol 2010, 28:18s. (abstr LBA4012).
40. Gillen S., Schuster T., Meyer Zum Buschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
41. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
42. Maisey N., Chau I., Cunningham D., et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002, 20:3130-3136.
43. Colucci G., Giuliani F., Gebbia V., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002, 94:902-910.
44. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509-3516.
45. Heinemann V., Wilke H., Mergenthaler H.G., et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000, 11:1399-1403.
46. Colucci G., Labianca R., Di Costanzo F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010, 28:1645-1651.
47. Poplin E., Feng Y., Berlin J., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:3778-3785.
48. Correale P., Montagnani F., Miano S., et al. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. J Chemother 2008, 20:119-125.
49. Novarino A., Chiappino I., Bertelli G.F., et al. Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 2004, 15:474-477.
50. Wagner A.D., Buechner-Steudel P., Wein A., et al. Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2007, 18:82-87.
51. Hess V., Pratsch S., Potthast S., et al. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol 2010, 21:2390-2395.
52. Fine R.L., Fogelman D.R., Schreibman S.M., et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008, 61:167-175.
53. Conroy T., Paillot B., Francois E., et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005, 23:1228-1236.
54. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
55. Goel A., Grossbard M.L., Malamud S., et al. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anticancer Drugs 2007, 18:263-271.
56. Reni M., Cordio S., Milandri C., et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005, 6:369-376.
57. Reni M., Passoni P., Panucci M.G., et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001, 19:2679-2686.
58. Reni M., Cereda S., Bonetto E., et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest 2007, 25:594-598.
59. Reni M., Cereda S., Bonetto E., et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2007, 59:361-367.
60. Reni M., Cereda S., Rognone A., et al. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 2012, 69:115-123.
61. Reni M., Cereda S., Balzano G., et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009, 115:2630-2639.
62. Reni M., Sartori N., Mambrini A., et al. An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. Anticancer Drugs 2010, 21:459-464.
63. Reni M., Pasetto L.M., Passardi A., et al. Treatment trends in metastatic pancreatic cancer patients: is it time to change?. Dig Liver Dis 2011, 43:225-230.